GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Price-to-Tangible-Book

TriSalus Life Sciences (TriSalus Life Sciences) Price-to-Tangible-Book : (As of May. 24, 2024)


View and export this data going back to 2023. Start your Free Trial

What is TriSalus Life Sciences Price-to-Tangible-Book?

As of today (2024-05-24), TriSalus Life Sciences's share price is $7.1012. TriSalus Life Sciences's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $-1.35. Hence, TriSalus Life Sciences's Price to Tangible Book Ratio of today is .

The historical rank and industry rank for TriSalus Life Sciences's Price-to-Tangible-Book or its related term are showing as below:

During the past 3 years, TriSalus Life Sciences's highest Price to Tangible Book Ratio was 17.96. The lowest was 17.96. And the median was 17.96.

TLSI's Price-to-Tangible-Book is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.7
* Ranked among companies with meaningful Price-to-Tangible-Book only.

A closely related ratio is called PB Ratio. As of today, TriSalus Life Sciences's share price is $7.1012. TriSalus Life Sciences's Book Value per Sharefor the quarter that ended in Mar. 2024 was $-1.31. Hence, TriSalus Life Sciences's P/B Ratio of today is .

TriSalus Life Sciences Price-to-Tangible-Book Historical Data

The historical data trend for TriSalus Life Sciences's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TriSalus Life Sciences Price-to-Tangible-Book Chart

TriSalus Life Sciences Annual Data
Trend Dec21 Dec22 Dec23
Price-to-Tangible-Book
- - -

TriSalus Life Sciences Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only - - 17.96 - -

Competitive Comparison of TriSalus Life Sciences's Price-to-Tangible-Book

For the Medical Devices subindustry, TriSalus Life Sciences's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TriSalus Life Sciences's Price-to-Tangible-Book Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TriSalus Life Sciences's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where TriSalus Life Sciences's Price-to-Tangible-Book falls into.


TriSalus Life Sciences Price-to-Tangible-Book Calculation

TriSalus Life Sciences's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=7.1012/-1.347
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price to Tangible Book=Market Cap/Tangible Equity
=Market Cap/(Total Stockholders Equity-Preferred Stock-Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

TriSalus Life Sciences Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of TriSalus Life Sciences's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

TriSalus Life Sciences (TriSalus Life Sciences) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TriSalus Life Sciences Inc (NAS:TLSI) » Definitions » Price-to-Tangible-Book
Comparable Companies
INGN HYBT HYPR CLPT ELMD TELA MGRM AXDX APYX NSPR ABT SYK MDT BSX SZSE:300760 EW DXCM ZBH STE XAMS:PHIA
Traded in Other Exchanges
N/A
Address
6272 W. 91st Avenue, Westminster, CO, USA, 80031
Website
https://trisaluslifesci.com
TriSalus Life Sciences Inc is an oncology company integrating standard-of-care treatments and its investigational immunotherapeutic, SD-101, with disruptive Pressure Enabled Drug Delivery infusion systems to transform the treatment paradigm for patients battling liver and pancreatic tumors. TriSalus is a commercial-stage medical device and Phase I clinical-stage pharmaceutical company.
Executives
Jodi Devlin officer: President, Therapeutics C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
James Alecxih officer: President, Device Technology C/O NEVRO CORP., 1800 BRIDGE PARKWAY, REDWOOD CITY CA 94065
Bryan F. Cox officer: Chief Scientific & Manufact. C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Kerry R Hicks director C/O HEALTHGRADES.COM, 44 UNION BLVD SUITE 600, LAKEOOD CO 80228
George Kelly Martin director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Jennifer Stevens officer: Chief Regulatory Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Richard Marshak officer: Sr.VP, Corp. Dev. & Strategy C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mary T Szela director, officer: CEO and President 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Anil K. Singhal director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Sean Murphy director, officer: Chief Financial Officer C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703
Arjun Jj Desai director C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Steven C Katz officer: Chief Medical Officer C/O TRISALUS LIFE SCIENCES, INC., 6272 W. 91ST AVENUE, WESTMINSTER CO 80031
Mats Wahlstrom director, 10 percent owner 500 GOLDEN RIDGE ROAD, SUITE 100, GOLDEN CO 80401
Von Eschenbach Andrew C. director C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Equity Ab Frankenius 10 percent owner BOX 984, BORAS V7 SE-501 10